Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

被引：0
|
作者：
Min Huang
M. Catherine Pietanza
Ayman Samkari
James Pellissier
Thomas Burke
Sheenu Chandwani
Fansen Kong
A. Simon Pickard
机构：
[1] Merck & Co.,Centre for Observational and Real
[2] Inc.,world Evidence
[3] Second City Outcomes Research,undefined
来源：
PharmacoEconomics | 2019年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 116
页数：11
相关论文
共 50 条
  • [31] Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer
    Li, Li
    Xu, Chunhua
    Wang, Wei
    Zhang, Qian
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [32] PD-L1 expression in driver-mutated metastatic non-small cell lung cancer
    de Jager, V.
    Garcia, B. N. Cajiao
    Hempenius, M. A.
    Kuijpers, C. C.
    van Kempen, L. C.
    Schuuring, E.
    van der Wekken, A. J.
    Willems, S. M.
    VIRCHOWS ARCHIV, 2024, 485 : S139 - S139
  • [33] The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Zhang, Shuling
    Bai, Xueli
    Shan, Fengping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [34] Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
    Kallergi, Galatea
    Vetsika, Eleni-Kyriaki
    Aggouraki, Despoina
    Lagoudaki, Eleni
    Koutsopoulos, Anastasios
    Koinis, Filippos
    Katsarlinos, Panagiotis
    Trypaki, Maria
    Messaritakis, Ippokratis
    Stournaras, Christos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [35] Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
    Dori, Shani Ben
    Aizic, Asaf
    Sabo, Edmond
    Hershkovitz, Dov
    LUNG CANCER, 2020, 147 : 91 - 98
  • [36] Association between very high PD-l1 expression versus high PD-l1 expression in patients receiving pembrolizumab as firstline treatment for advanced non-small cell lung cancer
    Shah, Syed Mohsin Mahmood
    Marmarelis, Melina
    Mamtani, Ronac
    Hubbard, Rebecca
    Hennessy, Sean
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 96 - 97
  • [37] The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma
    Wang, H.
    Agulnik, J.
    Kasymjanova, G.
    Fiset, P. O.
    Camilleri-Broet, S.
    Redpath, M.
    Cohen, V
    Small, D.
    Pepe, C.
    Sakr, L.
    Spatz, A.
    LUNG CANCER, 2019, 132 : 36 - 38
  • [38] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [39] PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER
    DiBonaventura, M.
    Meyers, A.
    Higginbottom, K.
    Morimoto, Y.
    Ilacqua, J.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [40] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
12345